艾美捷科技特约代理Atlas Antibodies抗体产品。

Atlas Antibodies公司开发与人类蛋白有关的抗体以及试剂，基于质谱（MS）的定量蛋白质组学，在人体中可能的20,000种蛋白质编码基因中，Atlas已经具有覆盖15,000种的基因产物，超过17,000种抗体，约13,000种蛋白质靶标。

At Atlas Antibodies we have a very clear mission: To provide our customers with advanced research reagents targeting all human proteins. The Human Protein Atlas (HPA) project released the first version of a complete tissue-based map of human protein expression using antibodies in November 2014. In close partnership with the HPA project, we continue to develop advanced antibodies and advanced reagents for Mass Spectrometry (MS)-based quantitative proteomics. Of the possible 20,000 protein coding genes in the human body we already have over 21,000 antibodies covering 15,000 gene products. Learn more in this in the video below.

Atlas Antibodies公司的主要产品包括：

Primary Antibodies

All Primary Antibodies

Triple A Polyclonals

PrecisA Monoclonals

Blocking Antigens

MS Standards

QPrESTs

Laminin Markers

Neuroscience Markers

EMT Markers

艾美捷科技代理Clearsynth品牌全系列产品

Clearsynth研发中心位于海得拉巴，以“创新与精准之心”为核心理念，打造了一个精心设计的空间，旨在激发突破性的发现并提升可能性的界限。专注于创新有机化学和独特复杂分子的合成，涵盖稳定同位素标记化合物、代谢物、杂质、葡萄糖醛酸、手性化合物、共轭物杂质和放射性标记化合物等。承接复杂分子或“难以合成”的合成化合物/中间体的定制合成服务。提供超过3,59,000个高纯度参考标准品，Clearsynth公司的产品线包括稳定同位素、原料药、杂质、亚硝胺、二级标准、散装化合物等。

▍Clearsynth服务领域

● 小分子：合成各种精细化学品和化合物，用于从毫克到数公斤规模的小分子药物发现。

● 工艺开发：开发新的合成路线，也可以修改和优化客户提供的工艺。

● 合同研发综合：专注于从临床前阶段到III期以及成功的技术转让。

● 生物核磁共振服务：位于海得拉巴的符合GLP标准的高场生物核磁共振/600MHz和300MHz设施，由敬业且经验丰富的核磁共振操作员提供支持。

● CDMO服务：致力于复杂、危险和可持续的产品和工艺。

● 分析服务：符合FDA、BIS、卫生部和其他标准机构制定的所有监管规范。

▍Clearsynth部分产品列表

艾美捷科技特约代理Avidity Biosciences公司产品。

Avidity Biosciences公司位于美国加州La Jolla，是一家专门从事抗体寡核苷酸结合物（AOC™）技术开发的生物技术公司，此项技术结合了单抗组织选择性和寡核苷酸疗法的精确性，克服了寡核苷酸给药屏障。

Avidity Biosciences is a privately-held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.

Antibody oligonucleotide conjugate (AOC™) technology

Avidity’s antibody oligonucleotide conjugate (AOC™) technology utilizes antibodies to target cells and tissues of interest and facilitate the uptake and internalization of oligonucleotide payloads. By combining the cellular and tissue selectivity of antibodies with the selectivity and efficiency of oligo-based approaches, Avidity has demonstrated modulation of disease-related RNAs in diverse cell types and tissues including muscle, heart, liver, tumors and immune cells.